NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model

Clinical Cancer Research

Volumn 12, Issue 22, 2006, Pages 6758-6764

  Cusack Jr , James C ^a,b   Liu, Rong ^a   Xia, Lijun ^a   Chao, Ta Hsiang ^c   Pien, Christine ^c   Niu, Wei ^c   Palombella, Vito J ^c   Neuteboom, Saskia T C ^c   Palladino, Michael A ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Nereus Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; BORTEZOMIB; FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; NPI 0052; OXALIPLATIN; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; COLON CANCER; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE; COLONIC NEOPLASMS; DRUG ADMINISTRATION ROUTES; DRUG SYNERGISM; FEMALE; HUMANS; LACTONES; MICE; MICE, NUDE; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; PYRROLES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33845288930     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1151     Document Type: Article

References (20)

1. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
2. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002;6:493-500.
3. Cusack JC, Jr., Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001;61:3535-40.
4. Russo SM, Tepper JE, Baldwin AS, Jr., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 2001;50:183-93.
5. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed Engl 2003;42:355-7.
6. Macherla VR, Mitchell SS, Manam RR, et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 2005;48:3684-7.
7. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005;8:407-19.
8. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000;46:673-83.
9. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
10. Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
11. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5:412-7.
12. Hogan PC, Corey EJ. Proteasome inhibition by a totally synthetic β-lactam related to salinosporamide A and omuralide. J Am Chem Soc 2005;127:15386-7.
13. Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer-more than skin deep. J Clin Oncol 2005;23:5374-85.
14. Schultz RM. Dawn of a new era in molecular cancer therapeutics. Prog Drug Res 2005;63:1-17.
15. Boyer J, Allen WL, McLean EG, et al. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 2006;66:2765-77.
16. Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004;91:1931-46.
17. Van Geelen CM, de Vries EG, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 2004;7:345-58.
18. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004;64:4912-8.
19. Nawrocki ST, Bruns CJ, Harbison MT, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002;1:1243-53.
20. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26 S proteasome. J Surg Res 2001;100:11-7.